Blueprint Medicines (BPMC) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Blueprint Medicines (BPMC) PT Raised to $70 at Wedbush
November 1, 2017 7:17 AM EDTWedbush analyst David Nierengarten raised his price target on Blueprint Medicines (NASDAQ: BPMC) to $70.00 (from $66.00) while maintaining a Outperform rating after the company reported enrollment progress across a number of studies of their wholly-owned kinase assets, and reiterated timeline for future trial... More
